4D Molecular Therapeutics(FDMT)
Focus: 4D Molecular Therapeutics is a public gene therapy company focused on in vivo genetic medicines for rare and serious diseases, with a diversified pipeline across ophthalmology, metabolic, and respiratory indications. The company operates at clinical-stage with Phase 1 through Phase 3 programs but minimal revenue generation.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
7+3 this month
Stable — net +3 jobs in 30d
11 added, 8 removed. Backfill posture.
Should You Work at 4D Molecular Therapeutics?
AI assessmentBest suited for mission-driven early-career gene therapy scientists seeking high risk/high reward exposure; unsuitable for those prioritizing near-term cash stability or established infrastructure.
Why Work Here
- Early-stage gene therapy exposure: 6 active programs across Phase 1-3, offering hands-on involvement in cutting-edge modality development with potential for significant clinical milestones
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$37K
Pipeline & Clinical Trials
Observation
ChoroideremiaClinical Trials (2)
NCT045171494D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
Phase 1/2Help build intelligence for 4D Molecular Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.